ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

ACS to Being Review Of Facilities Survey Proposals; Working Group Established

May 25, 1984

Advisors tell NCI to rethink contracts for clinical trials cooperative group tissue banks

November 21, 2003

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

May 30, 2003

In Brief: House Bill Boosts NIH Funding By $1.2 Billion; ASCO Counted More Than 17,000 Registrants

June 26, 1998

NCI Taps Harlow To Head Office of Science Policy

July 26, 1996

FASEB Delivers Its Recommendations For Federal Research Funding in 2013

February 3, 2012